S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Critical asset just had biggest fall on record (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Critical asset just had biggest fall on record (Ad)
Roku stock and the mother of all entry opportunities
Rivian shares gets discounted; shares can move lower 
Critical asset just had biggest fall on record (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Critical asset just had biggest fall on record (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Critical asset just had biggest fall on record (Ad)
Roku stock and the mother of all entry opportunities
Rivian shares gets discounted; shares can move lower 
Critical asset just had biggest fall on record (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Critical asset just had biggest fall on record (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Critical asset just had biggest fall on record (Ad)
Roku stock and the mother of all entry opportunities
Rivian shares gets discounted; shares can move lower 
Critical asset just had biggest fall on record (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Critical asset just had biggest fall on record (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Critical asset just had biggest fall on record (Ad)
Roku stock and the mother of all entry opportunities
Rivian shares gets discounted; shares can move lower 
Critical asset just had biggest fall on record (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:LGND

Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis

$73.56
+0.89 (+1.22%)
(As of 02/22/2024 ET)
Today's Range
$71.84
$74.00
50-Day Range
$67.35
$76.45
52-Week Range
$49.24
$85.70
Volume
94,647 shs
Average Volume
107,646 shs
Market Capitalization
$1.28 billion
P/E Ratio
108.18
Dividend Yield
N/A
Price Target
$116.33

Ligand Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
58.1% Upside
$116.33 Price Target
Short Interest
Bearish
5.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
0.30mentions of Ligand Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-29.54%
From $4.13 to $2.91 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.12 out of 5 stars

Medical Sector

283rd out of 934 stocks

Pharmaceutical Preparations Industry

119th out of 423 stocks


LGND stock logo

About Ligand Pharmaceuticals Stock (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.

LGND Stock Price History

LGND Stock News Headlines

Why Banks Could See a "Cash Frenzy" on March 11
He called the Lehman Brothers collapse in 2008… the Bitcoin crash in 2018… and the inflation crisis of 2022. Now, he's warning that the 2023 banking crisis is not over yet. Instead, we could see a cash frenzy at banks as soon as March 11. Do NOT buy another stock until you
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Biotech Stocks Facing FDA Decision In January 2024
13 Most Promising Small-Cap Stocks According to Analysts
Ligand Pharmaceuticals Inc (LGDN.MU)
See More Headlines
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
2/22/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LGND
CUSIP
53220K50
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$116.33
High Stock Price Target
$144.00
Low Stock Price Target
$95.00
Potential Upside/Downside
+58.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-33,360,000.00
Pretax Margin
46.03%

Debt

Sales & Book Value

Annual Sales
$196.24 million
Cash Flow
$5.17 per share
Book Value
$35.37 per share

Miscellaneous

Free Float
15,550,000
Market Cap
$1.28 billion
Optionable
Optionable
Beta
1.01
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Todd C. Davis Ph.D. (Age 63)
    CEO & Director
    Comp: $743.49k
  • Mr. Matthew E. Korenberg (Age 49)
    President & COO
    Comp: $760.99k
  • Mr. Octavio Espinoza (Age 53)
    Chief Financial Officer
    Comp: $457.19k
  • Mr. Andrew T. Reardon J.D. (Age 49)
    Chief Legal Officer & Secretary
    Comp: $480.16k
  • Mr. Paul J. Hadden
    Senior Vice President of Investments & Business Development
  • Simon Latimer
    Head of Investor Relations
  • Mr. Todd Pettingill
    Director of Corporate Development
  • Ms. Audrey Warfield-Graham
    Chief People Officer
  • Dr. Keith Marschke
    Senior Vice President of Biology & Scientific Affairs
  • Dr. Vincent D. Antle (Age 55)
    Senior Vice President of Technical Operations & QA - Capitsol














LGND Stock Analysis - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LGND shares.
View LGND analyst ratings
or view top-rated stocks.

What is Ligand Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 1-year price objectives for Ligand Pharmaceuticals' shares. Their LGND share price targets range from $95.00 to $144.00. On average, they expect the company's stock price to reach $116.33 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price.
View analysts price targets for LGND
or view top-rated stocks among Wall Street analysts.

How have LGND shares performed in 2024?

Ligand Pharmaceuticals' stock was trading at $71.42 on January 1st, 2024. Since then, LGND stock has increased by 3.0% and is now trading at $73.56.
View the best growth stocks for 2024 here
.

When is Ligand Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our LGND earnings forecast
.

How can I listen to Ligand Pharmaceuticals' earnings call?

Ligand Pharmaceuticals will be holding an earnings conference call on Tuesday, February 27th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its earnings results on Wednesday, November, 8th. The biotechnology company reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.34. The biotechnology company had revenue of $32.87 million for the quarter, compared to analyst estimates of $27.22 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 9.67% and a net margin of 9.09%. The company's revenue for the quarter was down 44.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.20) earnings per share.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY 2028 earnings guidance on Tuesday, December, 12th. The company provided earnings per share (EPS) guidance of 10.000-10.500 for the period. The company issued revenue guidance of -.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.82%), Dimensional Fund Advisors LP (3.81%), Stephens Investment Management Group LLC (3.80%), Villere ST Denis J & Co. LLC (2.47%), Pacer Advisors Inc. (1.88%) and abrdn plc (1.67%). Insiders that own company stock include Andrew Reardon, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis.
View institutional ownership trends
.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LGND) was last updated on 2/23/2024 by MarketBeat.com Staff